engleski

Current state of-the-art of concomitant chemoradiation in cervical carcinomas

Current state-of-the-art of concomitant chemoradiation in cervical carcinomas. Vrdoljak E, Hamm W. Center of Oncology, University of Split School of Medicine, Clinical Hospital of Split, Croatia. Despite screening programs, cervical carcinoma remains a major health problem throughout the world. Until recently pelvic radiation has been the standard therapy for advanced disease with overall five-year survival rates of 50%. Recently, five randomized trials demonstrated a significant survival advantage for the concomitant administration of radiotherapy and cisplatin-based chemotherapy. Although the trials vary somewhat in terms of stage of disease, dose of radiation, and schedule of radiation and cisplatin, they all demonstrated a significant survival benefit for the combined approach. Congruent to these findings are results from a meta-analysis based on the data from 19 trials with 4, 580 randomized patients. The absolute increase in progression-free and overall survival was 16% and 12%, respectively. Contrary to these findings is the result of the National Cancer Institute of Canada (NCCI) trial. Despite that result cisplatin-based concomitant chemoradiotherapy has become the standard treatment of locally advanced cervical cancer.

Cervical cancer; Concomitant chemoradiotherapy; Cisplatin

nije evidentirano